Delivery Order SPE2DB20D2002-SPE2DB25FL79Z
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Eliquis 5 mg tablets (60-count units) with a ceiling value of $10,243.60. This firm fixed-price delivery order, which is set to be completed by August 6, 2025, represents a single-award contract with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) with a ceiling value of $18,978.90. This non-set-aside competitive award is scheduled for completion by August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Eliquis 2.5 mg tablets (60-count) at a firm fixed price of $3,931.20. This non-competitive delivery order, with an ultimate completion date of August 25, 2025, represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the Department of Defense medical supply chain. The contract will be performed at the contractor's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Eliquis 5 mg tablets (60-count units) with a contract ceiling value of $55,353.92. This competitively awarded, firm fixed-price delivery order is scheduled for completion by June 20, 2025, and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government. The work will be performed at the company's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Eliquis 2.5 mg tablets (60-count units) at a ceiling value of $1,556.10. This contract represents a firm fixed price delivery order under a non-set-aside competitive procurement and is scheduled for ultimate completion on August 26, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Eliquis is a prescription...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,228.50 on September 3, 2025, for the supply of Eliquis 2.5 mg tablets (60-count package). This firm fixed price, competitively awarded delivery order represents a non-set-aside procurement and is scheduled for completion by September 4, 2025. The product will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Eliquis 2.5 mg tablets (60-count packaging) with a ceiling value of $1,228.50. This is a firm fixed-price delivery order with an ultimate completion date of July 25, 2025, and no set-aside designation was applied. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location. The award represents a small-value...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) with a ceiling value of $41,338.69. This firm fixed-price delivery order is scheduled for completion by July 28, 2025, and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the contractor's capability to meet federal...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) valued at $27,727.45. The contract represents a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count units) with a ceiling value of $1,965.60. The award, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, carries firm fixed pricing and represents a non-set-aside competitive procurement. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB20D2002Indefinite Delivery Contract
- SPE2DB20D2002-SPE2DB25FL79ZDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,228.50 to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count packages) on September 25, 2025. The contract represents a firm fixed-price delivery order with an ultimate completion date of September 26, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation applied. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a prime pharmaceutical vendor to the Defense Logistics Agency, AmerisourceBergen Drug Corp supplies a comprehensive range of medications and medical supplies to support military healthcare systems worldwide. The Eliquis delivery supports the federal government's pharmaceutical procurement needs, with the product serving as an anticoagulant medication for eligible military beneficiaries and veteran populations served through the Defense Health Agency and broader DLA medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 9/25/25 |